Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	37.36	40.79	45.79	35.44	11.36	55.74
Short-Term Investments	13.47	14.99	2.02	0.05	46.52	2.62
Cash & Short-Term Investments	50.83	55.78	47.81	35.49	57.88	58.36
Cash Growth	20.20%	16.68%	34.69%	-38.67%	-0.83%	40.41%
Accounts Receivable	0.96	1.56	0.64	0.75	0.3	50.84
Receivables	0.96	1.56	0.64	0.75	0.3	50.84
Prepaid Expenses	1.16	1.79	2.55	2.2	1.83	2.35
Other Current Assets	0.02	0.02	-	-	-	-
Total Current Assets	52.97	59.16	51	38.44	60	111.55
Property, Plant & Equipment	4.48	4.7	4.4	4.77	5.67	4.87
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	31.7	31.7	46.54	46.56	46.69	46.82
Long-Term Deferred Tax Assets	5.8	5.8	-	-	-	-
Other Long-Term Assets	0.6	0.56	0.61	0.58	0.63	0.63
Total Assets	106.22	112.58	113.22	101.02	123.66	174.55

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.54	2.34	1.17	2.05	2.39	3.54
Accrued Expenses	3.85	4.84	4.26	4.22	6.22	24.25
Current Portion of Leases	0.95	0.85	1.15	0.88	0.95	0.83
Current Unearned Revenue	1.68	3.33	7.39	10.81	9.42	18.12
Other Current Liabilities	-	-	-	-	-	0.38
Total Current Liabilities	8.02	11.37	13.98	17.96	18.98	47.12
Long-Term Leases	1.35	1.57	1.36	2.07	2.94	1.97
Long-Term Unearned Revenue	12.34	12.38	14.43	18.69	27.73	32.45
Long-Term Deferred Tax Liabilities	0.02	0.02	0.27	0.27	2.08	2.08
Other Long-Term Liabilities	24.7	43.91	6.16	-	0	0.03
Total Liabilities	46.42	69.24	36.21	39	51.73	83.65

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	535.72	515.47	484.72	451.34	440.28	434.53
Retained Earnings	-470.33	-467	-403.47	-384.86	-363.37	-337.1
Comprehensive Income & Other	-4.47	-3.92	-2.88	-3.07	-3.57	-5.21
Total Common Equity	60.92	44.55	78.38	63.42	73.34	92.22
Minority Interest	-1.12	-1.2	-1.37	-1.4	-1.4	-1.32
Shareholders' Equity	59.8	43.35	77.01	62.02	71.94	90.9
Total Liabilities & Equity	106.22	112.58	113.22	101.02	123.66	174.55

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2.3	2.42	2.51	2.95	3.9	2.8
Net Cash (Debt)	48.53	53.36	45.29	32.54	53.98	55.56
Net Cash Growth	20.92%	17.82%	39.19%	-39.72%	-2.84%	47.22%
Net Cash Per Share	0.20	0.23	0.23	0.19	0.32	0.34
Filing Date Shares Outstanding	252.91	249.09	228.36	188.53	170.15	169.71
Total Common Shares Outstanding	252.91	243.12	220.42	174.99	170.09	169.48
Working Capital	44.95	47.79	37.02	20.48	41.02	64.43
Book Value Per Share	0.24	0.18	0.36	0.36	0.43	0.54
Tangible Book Value	18.54	2.18	21.17	6.19	15.98	34.73
Tangible Book Value Per Share	0.07	0.01	0.10	0.04	0.09	0.20
Machinery	5.39	5.28	4.13	3.61	3.26	3.47
Leasehold Improvements	3	2.75	2.3	2.31	2.15	2.54

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error